散发性一期肾细胞癌经皮热消融后随访影像的风险分层方案开发
本研究回顾2002至2017年接受经皮微波消融或冷冻消融的256例活检证实散发性一期肾细胞癌患者,分析复发危险因素并构建风险分层随访影像方案。临床T分期和肿瘤分级为复发独立预测因素,据此分为降低风险组与升高风险组,两组5年无复发生存率分别为88%与69%。
要点
- 临床T分期(HR 2.46)和肿瘤分级(HR 4.17)是一期肾癌消融后复发的独立预测因素。
- 按有无危险因素分为降低风险组与升高风险组,升高风险组复发风险显著更高(HR 3.19)。
- 升高风险组可增加影像随访频率,降低风险组可减少随访频率。
核心结论
- 高核分级或T1b肿瘤在一期肾细胞癌经皮热消融后复发风险增加。
- 当前消融后随访方案可按个体复发风险调整,对升高风险患者增加影像频率,对降低风险患者减少影像频率。
研究设计与样本
- 回顾性纳入2002至2017年活检证实的散发性一期肾细胞癌患者256例(215例T1a,41例T1b),接受经皮微波消融178例或冷冻消融78例。
- 采用Kaplan-Meier法估计局部和远处无复发生存、癌症特异性生存及无转移生存,多变量模型识别复发危险因素。
主要发现
- 23例患者出现复发(16例局部,7例远处)。
- 复发与Nephrometry评分、囊性肿瘤、消融方式(冷冻消融 vs 微波消融)或性别无关。
- 5年癌症特异性生存率和无转移生存率分别为98.6%和97.4%。
关键数值与推荐
- 风险分层:降低风险一期(无危险因素)或升高风险一期(≥1个危险因素)。
- 危险因素为高核分级或T1b肿瘤。
临床怎么用
- 对高核分级或T1b的一期肾细胞癌消融后患者,可考虑更频繁的影像随访。
- 对无危险因素的患者,可考虑减少影像随访频率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze risk factors and patterns of RCC recurrence following percutaneous ablation for stage 1 tumors and develop risk-stratified follow-up imaging protocols. METHOD: Biopsy-proven sporadic stage 1 RCC patients treated with percutaneous microwave ablation (MWA) or cryoablation (CA) from 2002 to 2017 were included. Kaplan-Meier analysis was used to estimate local and distant recurrence-free survival, cancer-specific survival and metastatic-free survival. Multivariable models were used to identify risk factors associated with recurrence. RESULTS: A total of 256 patients with stage 1 RCC (215 T1a, 41 T1b) were treated with percutaneous MWA (178 subjects) or CA (78 subjects). Recurrence was identified in 23 patients (16 local, 7 distant). Clinical T stage (HR 2.46, 95% CI 1.06-5.72, P = .04) and tumor grade (HR 4.17, 95% CI 1.17-14.76, P = .03) were independent predictors of recurrence. Recurrence was not associated with Nephrometry score, cystic tumors, ablation modality (CA vs MWA) or gender. Five-year cancer-specific survival, and metastatic-free survival were 98.6% and 97.4%, respectively. Patients were stratified into 2 groups: reduced risk stage 1 (no risk factors) or elevated risk stage 1 (≥1 risk factor). Recurrence risk was higher in the elevated-risk group (HR = 3.19, 95% CI 1.35-7.53, P = .008). Five-year overall recurrence-free survival (local + distant) was higher in reduced-risk vs elevated-risk cohorts, 88% vs 69%, P = .005. CONCLUSION: High nuclear grade or T1b tumors have increased recurrence risk following percutaneous thermal ablation for stage 1 RCC. Current postablation follow-up protocols may be modified for individual recurrence risk to allow more frequent imaging for elevated-risk patients, while enabling less frequent imaging for reduced-risk patients.
引用
- Dreyfuss LD, Wells SA, Best SL, et al. Development of a Risk-stratified Approach for Follow-up Imaging After Percutaneous Thermal Ablation of Sporadic Stage One Renal Cell Carcinoma. Urology. 2019. PMID: 31465794. doi:10.1016/j.urology.2019.08.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。